FVIII Aurora:一种天然存在的增强FIXa亲和力的功能获得性FVIII变异体
在反复血栓形成和早亡患者中首次发现天然存在的增强效力FVIII变异体FVIII-R571S(FVIII Aurora)。重组FVIII-R571S体外研究显示其活化形式对FIXa亲和力增高10-20倍,导致FIXa依赖性A2结构域解离减少和APC介导灭活降低,从而产生功能性APC抵抗。在血友病A小鼠中,FVIII-R571S较野生型促凝效力增强4-5倍,并促进血小板和纤维蛋白积累。
要点
- FVIII-R571S是首个在血栓患者中发现的天然功能获得性FVIII变异体。
- 其活化形式对FIXa亲和力增高10-20倍,导致功能性APC抵抗。
- 在血友病A小鼠中促凝效力较野生型增强4-5倍。
核心结论
- FVIII-R571S的促血栓表型由FIXa亲和力增高驱动,增强FVIIIa-FIXa复合物组装和功能。
研究设计与样本
- 生成重组FVIII-R571S,进行体外生化研究和血友病A小鼠体内研究。
主要发现
- FVIII-R571S在一步法测定中活性增高6倍,而发色底物法活性与野生型相当。
- 活化的FVIII-R571S对FIXa亲和力增高10-20倍。
- FVIII-R571S可被APC和蛋白S灭活,与野生型类似,表明变异体本身并非固有APC抵抗。
- 在纯化和血浆研究中,FVIIIa-R571S对FIXa亲和力增高导致FIXa依赖性A2结构域解离减少和APC介导灭活降低。
- 在血友病A小鼠尾巴切割实验中,FVIII-R571S效力较野生型增高4-5倍;在血栓模型中,同等抗原水平下促进血小板和纤维蛋白积累显著增加。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Factor VIII Aurora (FVIII-R571S) is the first described naturally occurring enhanced-potency FVIII variant identified in a patient with recurrent thrombosis and early mortality. The patient's plasma exhibited increased procoagulant activity and reduced responsiveness to activated protein C (APC). To define the mechanism, we generated recombinant FVIII-R571S and performed in vitro and in vivo studies. Consistent with the clinical phenotype, FVIII-R571S demonstrated a 6-fold increase in one-stage assay activity, while chromogenic substrate assay activity was comparable to wild-type FVIII (FVIII-WT). This discrepancy was explained by biochemical studies showing that activated FVIII-R571S (FVIIIa-R571S) has 10-20-fold higher affinity for FIXa; notably, the chromogenic assay is insensitive to differences in FVIIIa-FIXa affinity. Additional analyses demonstrated that FVIII-R571S is inactivated by APC and protein S analogous to FVIII-WT, indicating that the variant is not intrinsically APC-resistant. However, the increased affinity of FVIIIa-R571S for FIXa confers FIXa-dependent reduced A2-domain dissociation and APC-mediated inactivation in purified and plasma-based studies. These enhanced biochemical properties translated in vivo to a more potent procoagulant phenotype in hemophilia A mice. In the tail clip assay, FVIII-R571S exhibited a 4-5-fold increase in potency compared to FVIII-WT. In a thrombosis model, FVIII-R571S promoted significantly increased platelet and fibrin accumulation relative to FVIII-WT at equivalent antigen levels. Collectively, these data demonstrate that the prothrombotic phenotype of FVIII-R571S is driven by increased FIXa affinity, which enhances FVIIIa-FIXa complex assembly and function. This same mechanism confers reduced A2 dissociation and functional APC resistance, providing a unifying explanation for the observed gain-of-function phenotype.
引用
- Morris JJ, Davidson RJ, Watson CT, et al. Factor VIII Aurora: A Naturally Occurring Gain of Function FVIII Variant with Enhanced FIXa Affinity. Blood. 2026. PMID: 42446089. doi:10.1182/blood.2026034515
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。